Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Should antidepressants be used for major depressive disorder?

    Research output: Contribution to journalReviewResearchpeer-review

  2. Dr. Uhre et al. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
Volume104
Issue number4
Pages (from-to)606-609
ISSN0009-9236
DOIs
Publication statusPublished - 13 Jul 2018

ID: 54833158